Suraksha Diagnostic Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Suraksha Diagnostic Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ₹4 per ₹100 of sales comes from others' credit, against ₹5 from others' credit three years earlier. Less money tied up than 94% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 52.6 times by its yearly operating cash. Higher than 92% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹235 of operating cash. Higher than 89% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹235Over the last 3 years, every ₹100 of reported profit came with ₹235 of operating cash.
Higher than 89% of Healthcare companies in India.
Self-Funding Ratio
1.3×Over the last 3 years its own operating cash covered its investment spending (capex) 1.3 times.
Lower than 51% of Healthcare companies in India.
Cash Locked Ratio
−₹4Money owed to suppliers is larger than money owed by customers plus stock: ₹4 per ₹100 of sales comes from others' credit, against ₹5 from others' credit three years earlier.
Less money tied up than 94% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹21Sales grew 63% in 3 years; of every extra ₹100 of sales, ₹21 became extra profit.
Higher than 65% of Healthcare companies in India.
Asset Productivity Ratio
+63% / +59%In 3 years sales changed by +63% while total assets changed by +59%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
52.6×Debt due within a year is covered 52.6 times by its yearly operating cash.
Higher than 92% of Healthcare companies in India.
Cash Cushion Ratio
−7%Debt, after subtracting cash, equals 7% of its market value (net debt).
Lower than 72% of Healthcare companies in India.
Tangible Assets Ratio
98%Of every ₹100 the company owns, ₹98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 56% of Healthcare companies in India.
Tangible Net Worth Ratio
97%Of every ₹100 of net worth, ₹97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 54% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Suraksha Diagnostic Limited owes ₹0.46 for every ₹1 it owns. Net profit rose 1% in the year to Mar 2026, and grew 70% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
43.5Investors pay ₹43.5 for every ₹1 of Suraksha Diagnostic Limited's yearly profit, higher than 61% of Healthcare companies in India.
P/B ratio
6.37The share price is 6.37 times Suraksha Diagnostic Limited's book value per share, higher than 70% of Healthcare companies in India.
Market cap
₹1,559 CrThe total market value of all of Suraksha Diagnostic Limited's shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹245 CrWhat Suraksha Diagnostic Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹47.01Net worth divided by the number of shares. The share price of ₹299.35 is 6.4 times this, which is the P/B above.
Return on equity (ROE)
14.6%Suraksha Diagnostic Limited earned 14.6% on its shareholders' money over the last year, higher than 59% of Healthcare companies in India.
Owes vs Owns
0.46×Suraksha Diagnostic Limited owes ₹0.46 for every ₹1 it owns (low), higher than 73% of Healthcare companies in India.
Dividend yield
0.16%Suraksha Diagnostic Limited pays 0.16% of its share price as dividends a year, lower than 75% of dividend-paying Healthcare companies in India.
Revenue growth
+23%Revenue rose 23% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Profit growth
+1%Net profit rose 1% in the year to Mar 2026, and grew 70% a year on average over 3 years.
Profit margin
10.4%Suraksha Diagnostic Limited keeps ₹10 of every ₹100 of revenue as net profit.
Cash quality
2.5×Cash from Suraksha Diagnostic Limited's business was 2.5× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
4.4×Suraksha Diagnostic Limited's operating profit covered its interest costs 4.4 times in the year to Mar 2026.
Cash vs debt
Net debtSuraksha Diagnostic Limited had ₹109 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Suraksha Diagnostic Limited's P/E ratio?
Investors pay ₹43.5 for every ₹1 of Suraksha Diagnostic Limited's yearly profit, higher than 61% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Suraksha Diagnostic Limited: ₹1,559 Cr ÷ ₹245 Cr (31 Mar 2026) = 6.4.
What is Suraksha Diagnostic Limited's return on equity?
Suraksha Diagnostic Limited earned 14.6% on its shareholders' money over the last year, higher than 59% of Healthcare companies in India.
How much does Suraksha Diagnostic Limited owe compared with what it owns?
Suraksha Diagnostic Limited owes ₹0.46 for every ₹1 it owns (low), higher than 73% of Healthcare companies in India.
Does Suraksha Diagnostic Limited pay a dividend?
Yes. Suraksha Diagnostic Limited pays 0.16% of its share price as dividends a year, lower than 75% of dividend-paying Healthcare companies in India.
Is Suraksha Diagnostic Limited's revenue growing?
Revenue rose 23% in the year to Mar 2026, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.